NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Phase 2 RENEW trial underway; interim data expected in H2 2026.

Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Credit: Rein Therapeutics
Already have an account? Sign in.
08/20/2026 · 11:35 AM
RNTX
/ Don’t stop at just one post.

Related↓

Maxim Initiates Buy Rating on Rein Therapeutics (RNTX) with $4 Price Target as LTI-03 Advances
07/20/2026 · 9:37 AM

Maxim Initiates Buy Rating on Rein Therapeutics with $4 Price Target as LTI-03 Advances

Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.

/ Subscriber only
/ Read more

Feed↓

Rigetti Shares Fall After Q3 Revenue Miss and Soft Full-Year Outlook
11/10/2026 · 4:30 PM

Rigetti Shares Fall After Q3 Revenue Miss and Soft Full-Year Outlook

Rigetti stock dropped after Q3 revenue of $1.4 million missed estimates and full-year guidance of about $20 million fell short of analyst expectations.

/ Subscriber only
CoreWeave Shares Rise After Strong Q3 Beat and Raised Guidance
Featured/ 11/10/2026 · 4:17 PM

CoreWeave Stock Climbs as Margins Expand Faster Than Expected

CoreWeave shares rose after a strong Q3 beat, with revenue up more than $1B sequentially and margins hitting double digits ahead of plan.

/ Subscriber only
PepGen Stock Soars on Best-in-Class Phase 2 Results for Myotonic Dystrophy Drug
Featured/ 11/10/2026 · 11:31 AM

PepGen Stock Soars on Best-in-Class Phase 2 Results for Myotonic Dystrophy Drug

Phase 2 FREEDOM2 results for PGN-EDODM1 deliver 46.5% mean splicing correction, functional improvements, and strong analyst support.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI